These filings come after FDA issued its latest warning to patients and healthcare professionals about the serious dangers of compounded GLP-1 drugs
Innovative plate-based internalization reagents designed to deliver accurate, high-throughput, and scalable insights for GPCR and ADC research
Cenexi reports an EBITDA breakeven for the quarter
The submission is supported by positive results from the Phase 3 AMPLIFY trial
Vasograin Plus represents a major advancement in the treatment of migraine
Treatment with the selective NaV1.8 pain signal inhibitor VX-993 after bunionectomy surgery did not meet the primary endpoint
he new version features a streamlined sample-to-analysis workflow, built-in HRD detection, faster turnaround, and lower tissue requirements
The performance was below anticipated levels, primarily due to external factors such as seasonal disruption that affected overall results
The request stemmed from a 2024 lawsuit by Rampart alleging Egg Medical had infringed its patent
Our specialty chemical businesses have continued to perform strongly, growing double digit YoY
Subscribe To Our Newsletter & Stay Updated
